Cetirizine ophthalmic - Nicox

Drug Profile

Cetirizine ophthalmic - Nicox

Alternative Names: AC-170; cetirizine ophthalmic solution, 0.24% - Nicox; ZERVIATE

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aciex Therapeutics
  • Developer NicOx
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Allergic conjunctivitis

Most Recent Events

  • 06 Mar 2018 Cetirizine ophthalmic - Nicox is available for licensing in World (excluding USA) as of 06 Mar 2018. www.nicox.com
  • 19 Dec 2017 Eyevance plans to launch Cetirizine ophthalmic for Allergic conjunctivitis in USA in late 2018
  • 21 Sep 2017 Cetirizine ophthalmic - Nicox market licensed to Eyevance Pharmaceuticals in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top